AZRX News and Press, AzurRx BioPharma Inc. From 09/25/19

Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Management to discuss the results on a call scheduled for today, September 25, 2019 at 8:30 a.m. Eastern Time NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharm...

AzurRX Biopharma (NASDAQ: AZRX ): Q2 GAAP EPS of -$0.25 misses by $0.03 . More news on: AzurRx BioPharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, reported financial results for...

The first patient has been dosed in a Phase 2 clinical trial evaluating Proteostasis Therapeutics' ( PTI -1.6% ) doublet therapy (PTI-808 and PTI-801) and triplet therapy (doublet + PTI-428) in up to 30 F508del homozygous cystic fibrosis (CF) patients and up to 30 F508del heterozygous ...

BROOKLYN, NY / ACCESSWIRE / July 22, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the closing and funding of its previously announced underwritten public offering of five million shares of its common stock at a price ...

American Electric Technologies (NASDAQ: AETI ) -39%  after stockholders approved share exchange transaction with Stabilis Energy. More news on: American Electric Technologies, Inc, Senseonics Holdings, Inc., Netflix, Inc., Stocks on the move, Read more ...

BROOKLYN, NY / ACCESSWIRE / July 17, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the pricing of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1...

Gainers:  Immuron (NASDAQ: IMRN ) +81% . Blue Apron Holdings (NYSE: APRN ) +49% . Moxian (NASDAQ: MOXC ) +35% . GAIN Capital Holdings (NYSE: GCAP ) +32% . Lonestar Resources (NASDAQ: LONE ) +19% . AVROBIO (NASDAQ: AVRO ) +17% . Dolphin Entertainment (NASDAQ: DLPN ) +16% . Bio-P...

Thinly traded nano cap AzurRx BioPharma (NASDAQ: AZRX ) is up  12%  after hours on light volume in response to the launch of a Phase 2 clinical trial evaluating MS1819-SD, combined with standard porcine enzyme replacement therapy (PERT), in cystic fibrosis patients with severe ex...

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it will have a management R&D update c...